Chemotherapy-Related Nausea and Vomiting: Etiology and Management

Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians’ and nurses’ estimation vs. patients’ reported outcomes

“…These factors include poor control with prior chemotherapy, female sex, a low chronic alcohol intake or history, and younger age [5][6][7][8]. Our data reveal that there are no significant differences between acute CINV and delayed CINV patients in terms of demographics, chemotherapy treatment and antiemetic treatment.…”

Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians’ and nurses’ estimation vs. patients’ reported outcomes

“…These factors include poor control with prior chemotherapy, female sex, a low chronic alcohol intake or history, and younger age [5][6][7][8]. Our data reveal that there are no significant differences between acute CINV and delayed CINV patients in terms of demographics, chemotherapy treatment and antiemetic treatment.…”

Comparing the effectiveness of behavioral treatment for chemotherapy-induced nausea and vomiting when administered by oncologists, oncology nurses, and clinical psychologists.

“…Recent data have supported the view that similar mechanisms may be involved in the development and expression of PNV (P. B. Jacobsen et al, 1988;Morrow, 1989a).…”

Nausea and Vomiting Remain a Significant Clinical Problem

“…This significant decrease in vomiting was independent of general factors known to influence the development of NV including: age, gender, and type of chemotherapy agent. 21 The trends over time analysis did not, however, show any change in the frequency or occurrence of treatment-related nausea. Similarly, the proportion of patients reporting nausea in the earlier cohort (treated prior to the availability of the 5-HT 3 receptor antagonists) was not significantly different from the proportion reporting the symptom in the comparison group of patients treated when these agents were in widespread use.…”

“…We therefore repeated the analysis examining duration of nausea and the two analyses on frequency of vomiting using regression models (linear or logistic as appropriate) that simultaneously covaried for those drugs that were more prevalent in the later group (i.e., Adriamycin (doxorubicin), Bleomycin, Carboplatin, Cisplatin, Dacarbazine, Taxol, Vepesid, and Dexamethasone) as well as for gender and age, two well researched prognostic indicators of NV development. 21 All three of these analyses showed significant differences between the earlier and later group (all, P s Ͻ .02).…”

Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians’ and nurses’ estimation vs. patients’ reported outcomes

“…These factors include poor control with prior chemotherapy, female sex, a low chronic alcohol intake or history, and younger age [5][6][7][8]. Our data reveal that there are no significant differences between acute CINV and delayed CINV patients in terms of demographics, chemotherapy treatment and antiemetic treatment.…”

Comparing the effectiveness of behavioral treatment for chemotherapy-induced nausea and vomiting when administered by oncologists, oncology nurses, and clinical psychologists.

“…Recent data have supported the view that similar mechanisms may be involved in the development and expression of PNV (P. B. Jacobsen et al, 1988;Morrow, 1989a).…”

Nausea and Vomiting Remain a Significant Clinical Problem

“…This significant decrease in vomiting was independent of general factors known to influence the development of NV including: age, gender, and type of chemotherapy agent. 21 The trends over time analysis did not, however, show any change in the frequency or occurrence of treatment-related nausea. Similarly, the proportion of patients reporting nausea in the earlier cohort (treated prior to the availability of the 5-HT 3 receptor antagonists) was not significantly different from the proportion reporting the symptom in the comparison group of patients treated when these agents were in widespread use.…”

“…We therefore repeated the analysis examining duration of nausea and the two analyses on frequency of vomiting using regression models (linear or logistic as appropriate) that simultaneously covaried for those drugs that were more prevalent in the later group (i.e., Adriamycin (doxorubicin), Bleomycin, Carboplatin, Cisplatin, Dacarbazine, Taxol, Vepesid, and Dexamethasone) as well as for gender and age, two well researched prognostic indicators of NV development. 21 All three of these analyses showed significant differences between the earlier and later group (all, P s Ͻ .02).…”

Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians’ and nurses’ estimation vs. patients’ reported outcomes

“…These factors include poor control with prior chemotherapy, female sex, a low chronic alcohol intake or history, and younger age [5][6][7][8]. Our data reveal that there are no significant differences between acute CINV and delayed CINV patients in terms of demographics, chemotherapy treatment and antiemetic treatment.…”

Comparing the effectiveness of behavioral treatment for chemotherapy-induced nausea and vomiting when administered by oncologists, oncology nurses, and clinical psychologists.

“…Recent data have supported the view that similar mechanisms may be involved in the development and expression of PNV (P. B. Jacobsen et al, 1988;Morrow, 1989a).…”

Nausea and Vomiting Remain a Significant Clinical Problem

“…This significant decrease in vomiting was independent of general factors known to influence the development of NV including: age, gender, and type of chemotherapy agent. 21 The trends over time analysis did not, however, show any change in the frequency or occurrence of treatment-related nausea. Similarly, the proportion of patients reporting nausea in the earlier cohort (treated prior to the availability of the 5-HT 3 receptor antagonists) was not significantly different from the proportion reporting the symptom in the comparison group of patients treated when these agents were in widespread use.…”

“…We therefore repeated the analysis examining duration of nausea and the two analyses on frequency of vomiting using regression models (linear or logistic as appropriate) that simultaneously covaried for those drugs that were more prevalent in the later group (i.e., Adriamycin (doxorubicin), Bleomycin, Carboplatin, Cisplatin, Dacarbazine, Taxol, Vepesid, and Dexamethasone) as well as for gender and age, two well researched prognostic indicators of NV development. 21 All three of these analyses showed significant differences between the earlier and later group (all, P s Ͻ .02).…”